Sign In
Buy PAVM
$4.68
-0.230 (-4.68%)
At Close: Jun 23, 2026
PAVmed (PAVM) Upgraded to Buy: Here's What You Should Know
01:01pm, Monday, 30'th Mar 2026
PAVmed (PAVM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
08:00am, Monday, 30'th Mar 2026
PAVmed strengthened its capital structure and relaunched its medical device portfolio under new leadership Veris Health advanced strategic partnership with OSU and progressed implantable physiological
PAVmed Inc. (PAVM) Shareholder/Analyst Call Prepared Remarks Transcript
11:25am, Friday, 27'th Mar 2026
PAVmed Inc. (PAVM) Shareholder/Analyst Call Prepared Remarks Transcript
Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
08:00am, Thursday, 26'th Mar 2026
Processed 3,664 EsoGuard ® tests and recognized 4Q25 revenue of $1.5 million Expanded EsoGuard access with U.S. Department of Veterans Affairs contract award and strengthened clinical evidence with p
PAVmed to Hold Fourth Quarter and Full Year 2025 Business Update Conference Call and Webcast on March 30, 2026
09:01am, Monday, 16'th Mar 2026
Conference Call and Webcast at 8:30 AM ET NEW YORK, March 16, 2026 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company
Lucid Diagnostics to Hold Fourth Quarter and Full Year 2025 Business Update Conference Call and Webcast on March 26, 2026
09:01am, Thursday, 12'th Mar 2026
Conference Call and Webcast at 8:30 AM ET NEW YORK, March 12, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical d
PAVmed Closes Preferred Stock and Senior Secured Note Financings, Eliminating All Previously Outstanding Convertible Securities
08:01am, Wednesday, 04'th Feb 2026
Series D Preferred Stock offering yielded $30 million of gross proceeds and includes warrants exercisable for up to an additional $30 million upon publication of a positive draft EsoGuard Medicare loc
Should you chase the rally in PAVmed stock after it quadrupled on Wednesday?
03:40pm, Wednesday, 21'st Jan 2026
PAVmed Inc (NASDAQ: PAVM) shares more than quadrupled on Wednesday after the company's subsidiary – Lucid Diagnostics – secured a major contract from the US government.
Lucid Diagnostics Awarded U.S. Department of Veterans Affairs Contract for EsoGuard®
08:00am, Wednesday, 21'st Jan 2026
NEW YORK, Jan. 21, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed
PAVmed Announces Reverse Stock Split
09:01am, Tuesday, 30'th Dec 2025
NEW YORK, Dec. 30, 2025 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnost
Lucid Diagnostics Announces Positive Data from the Largest Reported Real-World Experience of Esophageal Precancer Detection
08:01am, Tuesday, 09'th Dec 2025
Report includes nearly 12,000 patients who underwent Lucid's EsoGuard® Esophageal DNA Test on samples collected using its EsoCheck® Esophageal Cell Collection Device Real-world data confirm excellen
PAVmed Inc. (PAVM) Shareholder/Analyst Call Prepared Remarks Transcript
11:08am, Friday, 05'th Dec 2025
PAVmed Inc. (PAVM) Shareholder/Analyst Call Prepared Remarks Transcript
Lucid Diagnostics Named a GenomeWeb 2025 Best Places to Work Top-Ranking Honoree
08:15am, Thursday, 20'th Nov 2025
Recognized as the leading company in its size category in program honoring the top workplaces across the diagnostics and precision-medicine sectors NEW YORK , Nov. 20, 2025 /PRNewswire/ -- Lucid Dia
PAVmed Inc. (PAVM) Q3 2025 Earnings Call Transcript
11:31am, Thursday, 13'th Nov 2025
PAVmed Inc. ( PAVM ) Q3 2025 Earnings Call November 13, 2025 8:30 AM EST Company Participants Matt Riley Lishan Aklog - Chairman & CEO Dennis McGrath - President & CFO Conference Call Participants Ant
Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
08:15am, Thursday, 13'th Nov 2025
NEW YORK , Nov. 13, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVm
